NASDAQ:CPIX - Cumberland Pharmaceuticals Stock Price, News, & Analysis

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) announced its quarterly earnings data on Tuesday, August, 14th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.09. The specialty pharmaceutical company had revenue of $10.16 million for the quarter, compared to the consensus estimate of $9.94 million. Cumberland Pharmaceuticals had a negative net margin of 11.16% and a negative return on equity of 3.12%. View Cumberland Pharmaceuticals' Earnings History.

Cumberland Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Cumberland Pharmaceuticals.

1 analysts have issued 12 month price targets for Cumberland Pharmaceuticals' stock. Their predictions range from $8.75 to $8.75. On average, they expect Cumberland Pharmaceuticals' stock price to reach $8.75 in the next twelve months. This suggests a possible upside of 54.9% from the stock's current price. View Analyst Price Targets for Cumberland Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cumberland Pharmaceuticals.

Some companies that are related to Cumberland Pharmaceuticals include Clementia Pharmaceuticals (CMTA), AVEO Pharmaceuticals (AVEO), Synlogic (SYBX), Sienna Biopharmaceuticals (SNNA), ProMetic Life Sciences (PFSCF), MEI Pharma (MEIP), Corium International (CORI), Concert Pharmaceuticals (CNCE), Marinus Pharmaceuticals (MRNS), Selecta Biosciences (SELB), Catalyst Pharmaceuticals (CPRX), Innate Pharma (IPHYF), Seres Therapeutics (MCRB), BIOFRONTERA AG/ADR (BFRA) and Acer Therapeutics (ACER).

Media stories about CPIX stock have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cumberland Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also gave headlines about the specialty pharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Cumberland Pharmaceuticals.

Cumberland Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ariel Investments LLC (8.31%), Stonepine Capital Management LLC (7.66%), Dimensional Fund Advisors LP (5.55%) and Renaissance Technologies LLC (2.40%). Company insiders that own Cumberland Pharmaceuticals stock include Kenneth Krogulski, Michael Bonner and Thomas R Lawrence. View Institutional Ownership Trends for Cumberland Pharmaceuticals.

CPIX stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Cumberland Pharmaceuticals.

CPIX stock was purchased by a variety of institutional investors in the last quarter, including Ariel Investments LLC and Renaissance Technologies LLC. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals.

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CPIX stock can currently be purchased for approximately $5.65.

Cumberland Pharmaceuticals has a market capitalization of $86.56 million and generates $41.15 million in revenue each year. The specialty pharmaceutical company earns $-7,970,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Cumberland Pharmaceuticals employs 84 workers across the globe.

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]